Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Regeneration Technologies, Tutogen Medical Inc. deal

RTIX will acquire TTG for $246.9 million in stock, or about 23.4 million shares

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE